Information Provided By: 
Fly News Breaks for December 13, 2019
SRPT
Dec 13, 2019 | 07:01 EDT
Cantor Fitzgerald analyst Alethia Young thinks shares of Sarepta Therapeutics should rally 20%-30% on last night's news of golodirsen's FDA approval. The stock in premarket trading is up 34% to $134.59. The "market punished the shares when not approved in a big way, so what goes down must go up," Young tells investors in a research note. She keeps an Overweight rating on the shares with a $175 price target.
News For SRPT From the Last 2 Days
There are no results for your query SRPT
